Open a free Demat account & get ₹500 in stocks.Claim
Nifty 5022,687.650.88%H 22,784.55 · L 22,554.85as of 22 Oct, 3:31 PM IST|Sensex73,249.390.82%H 73,720.83 · L 73,005.11as of 22 Oct, 3:32 PM IST|Bank Nifty54,925.71.01%H 55,134.45 · L 54,459.35as of 22 Oct, 3:31 PM IST|USD / INR₹94.810.38%H ₹94.94 · L ₹94.31as of 2:53 AM IST|Gold Intl (10g)₹1,23,163.380.49%H ₹1,23,376.75 · L ₹1,23,108.51upd. 4:42 AM IST|Silver Intl (1kg)₹1,66,565.920.66%H ₹1,66,916.46 · L ₹1,66,352.55upd. 4:40 AM IST|Crude WTI₹9,392.630.4%H ₹9,407.8 · L ₹9,370.82upd. 4:42 AM IST|Bitcoin₹76,97,2693.34%H ₹78,25,873.92 · L ₹75,68,664.08upd. 4:45 AM IST|Ethereum₹2,25,6073.69%H ₹2,29,773.69 · L ₹2,21,440.31upd. 4:45 AM IST|Nifty 5022,687.650.88%H 22,784.55 · L 22,554.85as of 22 Oct, 3:31 PM IST|Sensex73,249.390.82%H 73,720.83 · L 73,005.11as of 22 Oct, 3:32 PM IST|Bank Nifty54,925.71.01%H 55,134.45 · L 54,459.35as of 22 Oct, 3:31 PM IST|USD / INR₹94.810.38%H ₹94.94 · L ₹94.31as of 2:53 AM IST|Gold Intl (10g)₹1,23,163.380.49%H ₹1,23,376.75 · L ₹1,23,108.51upd. 4:42 AM IST|Silver Intl (1kg)₹1,66,565.920.66%H ₹1,66,916.46 · L ₹1,66,352.55upd. 4:40 AM IST|Crude WTI₹9,392.630.4%H ₹9,407.8 · L ₹9,370.82upd. 4:42 AM IST|Bitcoin₹76,97,2693.34%H ₹78,25,873.92 · L ₹75,68,664.08upd. 4:45 AM IST|Ethereum₹2,25,6073.69%H ₹2,29,773.69 · L ₹2,21,440.31upd. 4:45 AM IST|
0%
Mutual Funds

HDFC Mutual Fund and ADIA Invest ₹777 Crore in Pharma Firm Corona Remedies

Arth Vani DeskPublished: 1 min read
HDFC Mutual Fund and ADIA Invest ₹777 Crore in Pharma Firm Corona Remedies

Source: Economictimes

Arth Insight · What this means for your wallet

Immediate action
Research Corona Remedies' financial performance and future prospects.
  • Increased institutional interest can signal potential future stock price appreciation for Corona Remedies.
  • This deal suggests confidence in the Indian pharmaceutical sector, potentially benefiting related investments.
  • While not a direct investment, it validates the sector's attractiveness to large, experienced investors.
Recommended for you
Start a SIP or compare top funds
Explore Mutual Funds
Listen to this article
AI voice · Podcast mode
Get IPO & market alerts free on Telegram / WhatsApp
AI Summary

Major institutional investors, led by HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA), have acquired stakes in Corona Remedies via a massive block deal. The shares were offloaded by existing investors Sepia Investments and Anchor Partners for approximately ₹777 crore.

Key Highlights
  • ▸HDFC Mutual Fund was the largest buyer in the ₹777 crore block deal for Corona Remedies.
  • ▸Global giants like ADIA and Invesco have also picked up stakes, showing international confidence.
  • ▸The sellers in this transaction were existing investors Sepia Investments and Anchor Partners.
  • ▸This deal highlights a strong institutional interest in the Indian pharmaceutical sector.
Key Takeaways
  • ✓HDFC Mutual Fund was the largest buyer in the ₹777 crore block deal for Corona Remedies.
  • ✓Global giants like ADIA and Invesco have also picked up stakes, showing international confidence.
  • ✓The sellers in this transaction were existing investors Sepia Investments and Anchor Partners.
  • ✓This deal highlights a strong institutional interest in the Indian pharmaceutical sector.

In a significant move within the Indian pharmaceutical landscape, several high-profile institutional investors have pooled their resources to pick up a substantial stake in Corona Remedies. The transaction, executed through block deals on the stock exchanges, underscores the growing appetite for established healthcare players among top-tier fund managers.

The Details of the Deal

Existing stakeholders Sepia Investments and Anchor Partners sold shares worth roughly ₹777 crore in the pharmaceutical company. While the exact percentage of the equity changed hands wasn't immediately specified, the sheer scale of the transaction—approaching nearly ₹800 crore—marks it as one of the notable institutional movements in recent weeks.

HDFC MF Leads the Buying Charge

HDFC Mutual Fund emerged as the most prominent buyer in this transaction, absorbing a significant portion of the offloaded shares. This move by India’s leading fund house suggests a strong conviction in the long-term growth prospects of Corona Remedies. By deploying capital here, HDFC MF’s fund managers are signaling that they see value in the company’s current market positioning.

Global Giants Join the Fray

The deal wasn't just limited to domestic players. A group of prestigious international and multi-strategy firms also participated in the buying spree, including:

  • ADIA (Abu Dhabi Investment Authority): The sovereign wealth fund’s participation highlights global interest in Indian pharma.
  • Aberdeen Entities: Known for their long-term investment approach.
  • Invesco and WhiteOak: These institutional heavyweights further validated the demand for the stock.

What This Means for Retail Investors

When 'smart money'—represented by the likes of HDFC MF and ADIA—moves into a specific company, it often serves as a quality check for retail investors. While block deals involve large quantities of shares being traded between institutions, they reflect the underlying demand and trust in the company's financial health and future earnings potential. For retail participants, seeing such a diverse group of global and local institutions accumulate shares provides a layer of institutional validation for the pharmaceutical sector at large.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. This is for informational purposes only and not investment advice.

Recommended for you
Products related to this story — compare & act
Smart picks
Nippon India Small Cap Fund
Nippon India Mutual Fund · Small Cap
12.6%
3Y CAGR
Parag Parikh Flexi Cap Fund
PPFAS Mutual Fund · Flexi Cap
12.4%
3Y CAGR
Mirae Asset ELSS Tax Saver Fund
Mirae Asset Mutual Fund · ELSS
10.8%
3Y CAGR
ICICI Prudential Balanced Advantage Fund
ICICI Prudential Mutual Fund · Hybrid
10.1%
3Y CAGR
HDFC Balanced Advantage Fund
HDFC Mutual Fund · Hybrid
10.0%
3Y CAGR
Axis ELSS- Tax Saver Fund
Axis Mutual Fund · ELSS
9.1%
3Y CAGR

Mutual fund data is sourced from AMFI and shown for information only — funds are subject to market risks. Read all scheme-related documents carefully. Some listings may be sponsored. Not investment advice.

Frequently Asked Questions

What is a block deal and why does it matter?

A block deal is a single transaction of a large number of shares (usually over 5 lakh shares or ₹5 crore in value) between two parties. It matters because it shows where large professional investors are putting their money.

Who are the major buyers in the Corona Remedies deal?

HDFC Mutual Fund was the lead buyer, joined by global entities such as ADIA (Abu Dhabi Investment Authority), Aberdeen, Invesco, and WhiteOak.

Does this mean I should immediately buy the stock?

Institutional interest is a positive sign, but retail investors should always check if the company aligns with their personal risk profile and financial goals before investing.

Stay ahead of the market

Join the Arth Vani channels

Daily news summaries, IPO & market alerts on Telegram and WhatsApp.

Related Stories

Mid-Cap SIPs: ₹12,000 Monthly Investment Could Have Grown to ₹12 Lakh in 5 Years
Mutual Funds

Mid-Cap SIPs: ₹12,000 Monthly Investment Could Have Grown to ₹12 Lakh in 5 Years

A monthly Systematic Investment Plan (SIP) of ₹12,000 in certain mid-cap mutual funds could have potentially grown to ₹12 lakh over a five-year period. This highlights the significant wealth creation potential offered by mid-cap equity funds in the Indian market, though specific fund names for this performance were not detailed in the source.

3d ago·2 min readListen
Flexi Cap vs Multi Cap Funds: Understanding Key Differences for Indian Investors
Mutual Funds

Flexi Cap vs Multi Cap Funds: Understanding Key Differences for Indian Investors

Indian investors often weigh Flexi Cap and Multi Cap mutual funds. While specific scheme data was not provided in the source material, understanding their core strategies, expense ratios, and historical returns (CAGR) is crucial for making informed investment decisions.

3d ago·2 min readListen
AMFI Mandates Social Media Declaration for All MFDs, Regardless of Accounts
Breaking
Mutual Funds

AMFI Mandates Social Media Declaration for All MFDs, Regardless of Accounts

The Association of Mutual Funds in India (AMFI) has issued a directive requiring all Mutual Fund Distributors (MFDs) to submit a declaration regarding their social media accounts. This mandate extends even to MFDs who do not actively maintain any social media presence, ensuring comprehensive oversight of communication channels.

3d ago·2 min readListen
Four Low-Cost Small Cap Mutual Funds Delivered Over 16% CAGR in Five Years: Report
Breaking
Mutual Funds

Four Low-Cost Small Cap Mutual Funds Delivered Over 16% CAGR in Five Years: Report

According to an ET Now report, four low-cost small-cap mutual fund schemes have delivered Compound Annual Growth Rates (CAGR) exceeding 16% over the past five years. This highlights the potential of small-cap funds when chosen with an eye on costs and held for the long term, despite their inherent volatility.

4d ago·2 min readListen